Tvardi Therapeutics (NASDAQ:TVRD) Cut to Sell at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen cut shares of Tvardi Therapeutics (NASDAQ:TVRD – Free Report) from a hold rating to a sell rating in a research report sent to investors on Monday morning.

A number of other research firms also recently weighed in on TVRD. Piper Sandler cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 22nd. Cantor Fitzgerald downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Barclays set a $5.00 price objective on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a research report on Monday, October 13th. Finally, Raymond James Financial downgraded Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 14th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $55.50.

Get Our Latest Report on TVRD

Tvardi Therapeutics Trading Up 1.7%

Shares of TVRD stock opened at $4.30 on Monday. The business’s 50 day moving average is $4.21 and its two-hundred day moving average is $19.14. Tvardi Therapeutics has a twelve month low of $3.74 and a twelve month high of $43.65. The company has a market capitalization of $40.33 million, a P/E ratio of -0.45 and a beta of 0.11.

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.24. Tvardi Therapeutics had a negative net margin of 585.37% and a negative return on equity of 282.16%.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new position in Tvardi Therapeutics during the second quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Tvardi Therapeutics in the second quarter worth $43,000. Headlands Technologies LLC acquired a new position in Tvardi Therapeutics in the second quarter valued at about $80,000. New York State Common Retirement Fund acquired a new position in Tvardi Therapeutics in the second quarter valued at about $92,000. Finally, Squarepoint Ops LLC bought a new stake in Tvardi Therapeutics during the third quarter worth about $318,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

(Get Free Report)

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.

Further Reading